3-deazaneplanocin has been researched along with Ovarian Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, J; Liu, PS; Ma, YH; Pang, YX; Shen, L | 1 |
| Chen, J; Fu, Y; Li, C; Pang, B; Shen, K; Zhao, J | 1 |
2 other study(ies) available for 3-deazaneplanocin and Ovarian Neoplasms
| Article | Year |
|---|---|
3-Deazaneplanocin A is a promising therapeutic agent for ovarian cancer cells.
Topics: Adenosine; Antineoplastic Agents; Apoptosis; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Inhibitors; Female; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Ovarian Neoplasms; Polycomb Repressive Complex 2 | 2013 |
EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
Topics: Adenosine; Carcinogenesis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Epigenetic Repression; Female; Gene Knockdown Techniques; Histones; Humans; Lysine; Methylation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polycomb Repressive Complex 2; rho GTP-Binding Proteins; RNA, Small Interfering; Survival Analysis; Tumor Suppressor Proteins | 2015 |